טוען...
Leveraging National Cancer Institute Programmatic Collaboration for Single Radiopharmaceutical Drug Master Files
Targeted radiopharmaceutical conjugates intended for therapeutic use often are made of three key components, a decaying radionuclide, a chemical chelator/linker, and a targeted molecular entity. The National Cancer Institute (NCI) Experimental Therapeutics Program has accepted four radiopharmaceutic...
שמור ב:
| הוצא לאור ב: | Front Oncol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6611355/ https://ncbi.nlm.nih.gov/pubmed/31316916 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00573 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|